CA2695304A1 - Derives de pyrimidine et de pyridine et leur utilisation pharmaceutique et leurs compositions - Google Patents

Derives de pyrimidine et de pyridine et leur utilisation pharmaceutique et leurs compositions Download PDF

Info

Publication number
CA2695304A1
CA2695304A1 CA2695304A CA2695304A CA2695304A1 CA 2695304 A1 CA2695304 A1 CA 2695304A1 CA 2695304 A CA2695304 A CA 2695304A CA 2695304 A CA2695304 A CA 2695304A CA 2695304 A1 CA2695304 A1 CA 2695304A1
Authority
CA
Canada
Prior art keywords
methyl
butyl
pentyl
propyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2695304A
Other languages
English (en)
Inventor
Mark E. Schnute
Jeffery Neal Carroll
Cathleen Elizabeth Hanau
Matthew David Mcreynolds
Jeffrey Allen Scholten
Joseph J. Mcdonald
Margaret L. Grapperhaus
Mark Alan Massa
Peter G. Ruminski
Michelle Ann Schmidt
Joseph Walter Strohback
Bruce Cameron Hamper
Theresa R. Fletcher
Michael David Rogers
Patrick Michael O'brien
Joe Nahra
Mark Anthony Morris
William Howard Roark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc.
Mark E. Schnute
Jeffery Neal Carroll
Cathleen Elizabeth Hanau
Matthew David Mcreynolds
Jeffrey Allen Scholten
Joseph J. Mcdonald
Margaret L. Grapperhaus
Mark Alan Massa
Peter G. Ruminski
Michelle Ann Schmidt
Joseph Walter Strohback
Bruce Cameron Hamper
Theresa R. Fletcher
Michael David Rogers
Patrick Michael O'brien
Joe Nahra
Mark Anthony Morris
William Howard Roark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc., Mark E. Schnute, Jeffery Neal Carroll, Cathleen Elizabeth Hanau, Matthew David Mcreynolds, Jeffrey Allen Scholten, Joseph J. Mcdonald, Margaret L. Grapperhaus, Mark Alan Massa, Peter G. Ruminski, Michelle Ann Schmidt, Joseph Walter Strohback, Bruce Cameron Hamper, Theresa R. Fletcher, Michael David Rogers, Patrick Michael O'brien, Joe Nahra, Mark Anthony Morris, William Howard Roark filed Critical Pfizer Inc.
Publication of CA2695304A1 publication Critical patent/CA2695304A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA2695304A 2007-08-02 2008-07-29 Derives de pyrimidine et de pyridine et leur utilisation pharmaceutique et leurs compositions Abandoned CA2695304A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95360407P 2007-08-02 2007-08-02
US60/953,604 2007-08-02
US1553307P 2007-12-20 2007-12-20
US61/015,533 2007-12-20
PCT/IB2008/002046 WO2009016498A1 (fr) 2007-08-02 2008-07-29 Dérivés de pyrimidine et de pyridine et leur utilisation pharmaceutique et leurs compositions

Publications (1)

Publication Number Publication Date
CA2695304A1 true CA2695304A1 (fr) 2009-02-05

Family

ID=39884254

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2695304A Abandoned CA2695304A1 (fr) 2007-08-02 2008-07-29 Derives de pyrimidine et de pyridine et leur utilisation pharmaceutique et leurs compositions

Country Status (8)

Country Link
EP (1) EP2185537A1 (fr)
JP (1) JP2010535192A (fr)
KR (1) KR20100045497A (fr)
CN (1) CN101815710A (fr)
AU (1) AU2008281509A1 (fr)
CA (1) CA2695304A1 (fr)
MX (1) MX2010001338A (fr)
WO (1) WO2009016498A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2616441B1 (fr) * 2010-09-17 2019-08-07 Purdue Pharma L.P. Composés de pyridine et ses utilisations
AR086113A1 (es) * 2011-04-30 2013-11-20 Abbott Lab Isoxazolinas como agentes terapeuticos
WO2015070366A1 (fr) * 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Dérivés d'imidazole et de triazole liés à aryle et leurs procédés d'utilisation pour améliorer la pharmacocinétique d'un médicament
EP3087060B1 (fr) * 2013-12-23 2020-05-13 Merck Sharp & Dohme Corp. Composés pyrimidone carboxamide utilisés en tant qu'inhibiteurs de pde2
WO2016145614A1 (fr) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Composés de triazolyl pyrimidinone en tant qu'inhibiteurs de pde2
US10287269B2 (en) 2015-03-26 2019-05-14 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as PDE2 inhibitors
EP3291817B1 (fr) 2015-05-05 2019-10-02 Merck Sharp & Dohme Corp. Composés d'hétéroaryl-pyrimidinone en tant qu'inhibiteurs de pde2
WO2016183741A1 (fr) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Composés de pyrimidinone amide en tant qu'inhibiteurs de pde2
WO2016191935A1 (fr) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. Composés 6-alkyle dihydropyrazolopyrimidinone utilisés en tant qu'inhibiteurs de pde2
WO2016192083A1 (fr) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Composés dihydropyrazolopyrimidinone utilisés en tant qu'en tant qu'inhibiteurs de pde2
WO2016209749A1 (fr) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Composés bicycliques pyrazolo/imidazolo substitués en tant qu'inhibiteurs de pde2
WO2017000276A1 (fr) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Composés hétérocycliques bicycliques utilisés en tant qu'inhibiteurs de pde2
WO2017000277A1 (fr) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclo-composés de triazole substitués utilisés en tant qu'inhibiteurs de pde2
MA45656A (fr) 2016-07-14 2021-03-24 Pfizer Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1
CN111574405A (zh) * 2020-06-11 2020-08-25 烟台显华化工科技有限公司 一种双烯类负性液晶化合物及其制备方法和应用
CN117098757A (zh) * 2021-02-02 2023-11-21 里米诺生物科学有限公司 Gpr84拮抗剂和其用途
WO2023238930A1 (fr) * 2022-06-10 2023-12-14 大鵬薬品工業株式会社 Analogues de composés azabicycliques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933298B2 (en) * 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
GB0403155D0 (en) * 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
JP2008523043A (ja) * 2004-12-08 2008-07-03 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー テトラゾリル−メチレンアミノ酸誘導体

Also Published As

Publication number Publication date
AU2008281509A1 (en) 2009-02-05
KR20100045497A (ko) 2010-05-03
MX2010001338A (es) 2010-04-21
JP2010535192A (ja) 2010-11-18
WO2009016498A8 (fr) 2010-11-11
WO2009016498A1 (fr) 2009-02-05
EP2185537A1 (fr) 2010-05-19
CN101815710A (zh) 2010-08-25

Similar Documents

Publication Publication Date Title
CA2695304A1 (fr) Derives de pyrimidine et de pyridine et leur utilisation pharmaceutique et leurs compositions
AU2020273302B2 (en) Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
US10640517B2 (en) Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
CA3124898C (fr) Intermediaire de compose heterocyclique, son procede de preparation et son utilisation
JP5583694B2 (ja) Ｃｂ２受容体を調節するピロリジン化合物
JP5453437B2 (ja) Ｃｂ２受容体を選択的に調節するスルホニル化合物
CA3085561A1 (fr) Azines triazoles d'acide cyclohexyle utilisees en tant qu'antagonistes de lpa
JP6356790B2 (ja) 新規ｃｙｐ１７阻害剤／抗アンドロゲン
WO2014030743A1 (fr) Composé hétérocyclique
AU2008247102A1 (en) 2 -pyridine carboxamide derivatives as sodium channel modulators
CA2884355C (fr) Derive d'imidazoline-5-one utile comme inhibiteurs d'acide gras synthasepour le traitement du cancer
JP2014528469A (ja) タンパク質キナーゼ阻害剤
IL197664A (en) Biaryl urea compounds, medicinal preparations containing them and their use in the preparation of drugs for treatment
TW200808736A (en) Inhibitors of C-FMS kinase
WO2007124322A1 (fr) Inhibiteurs de la kinase de c-fms
AU2013255441B2 (en) Substituted pyrazole compounds as CRAC modulators
JP2022517901A (ja) 環状尿素
AU2015414743A1 (en) Process for the preparation of kinase inhibitors and intermediates thereof
TW202235072A (zh) 用於治療ｔｒｐｍ３介導病症之雜環衍生物
CA2719785A1 (fr) Composes d'ether-benzylidene-piperidine-aryl-carboxamide utiles comme inhibiteurs de faah
EP2909170A1 (fr) Composés carbamate substitués et leur utilisation en tant qu'antagonistes du canal potentiel récepteur transitoire (trp)
TWI740903B (zh) 新穎吡咯啶衍生物
TW202246248A (zh) 羥基雜環烷-胺甲醯基衍生物
AU2008259542A1 (en) Hetero bicyclic carboxamide derivatives and their pharmaceutical use and compositions
WO2024121779A1 (fr) Inhibiteurs de la protéase de type papaïne (plpro)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead